MARKET

SNY

SNY

Sanofi FR
NASDAQ
47.71
+0.21
+0.44%
After Hours: 48.19 +0.48 +1.00% 19:10 12/20 EST
OPEN
46.92
PREV CLOSE
47.50
HIGH
47.90
LOW
46.89
VOLUME
2.49M
TURNOVER
--
52 WEEK HIGH
58.97
52 WEEK LOW
43.38
MARKET CAP
119.61B
P/E (TTM)
27.16
1D
5D
1M
3M
1Y
5Y
1D
Why Cytokinetics Stock Was a Nearly 5% Winner Today
The Motley Fool · 17h ago
Sanofi to buy China rights to Cytokinetics lead asset
Seeking Alpha · 1d ago
Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
TipRanks · 1d ago
Sanofi to acquire rights to develop, commercialize aficamten from Corxel
TipRanks · 1d ago
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
Barchart · 1d ago
Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China
Benzinga · 1d ago
Sanofi To Buy Rights To Develop Cytokinetics' Aficamten In Greater China From Corxel
NASDAQ · 1d ago
CYTOKINETICS INC - ELIGIBLE FOR UP TO $150 MILLION IN MILESTONE PAYMENTS FROM SANOFI
Reuters · 1d ago
More
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Webull offers Sanofi SA (ADR) stock information, including NASDAQ: SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.